Stifel Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold on Proposed Acquisition

May 7, 2026 4:43 PM

Stifel analyst Paul Matteis downgraded Kalvista Pharmaceuticals Inc (NASDAQ: KALV) from Buy to Hold with a price target of $27.00 (from $42.00).

For an analyst ratings summary and ratings history on Kalvista Pharmaceuticals Inc click here. For more ratings news on Kalvista Pharmaceuticals Inc click here.